29AA Extensive Human
Sermorelin
Synthetic 29-amino-acid fragment of endogenous GHRH that stimulates the pituitary to release growth hormone through the body's own feedback-controlled axis.
In Plain English: Sermorelin is a lab-made copy of the first 29 amino acids of growth hormone-releasing hormone (GHRH), the signal your hypothalamus sends to the pituitary to release GH. Rather than injecting growth hormone directly, sermorelin prompts your own pituitary to produce it — keeping the natural somatostatin brake in place so the system can't overshoot.
Research Maturity
Extensive Human (~29 registered clinical trials (1984-2005); formerly FDA-approved (Geref); observational data post-2005+ Studies)
Quick Facts
Focus
Endocrine Testing
GH Axis Modulation
Route
IV
SubQ
Origin
Synthetically derived from the N-terminal 29 amino acids of human GHRH, the shortest fragment retaining full biological activity. Originally developed by Serono as Geref (FDA approved 1990-2008 for pediatric GHD; voluntarily withdrawn for commercial reasons).
Mechanism
Binds GHRH receptor on anterior pituitary somatotrophs. Couples to Gs, stimulating adenylate cyclase and raising cAMP, activating PKA and triggering calcium influx. Drives pulsatile GH secretion and upregulates GHRHR gene expression. Somatostatin counter-regulation remains intact.
Outcome
Serum GH peak after stimulation, height velocity (cm/year), serum IGF-1 and IGF-BP3, lean body mass (DXA), fat mass, skin thickness, insulin sensitivity, QoL scores, cognitive performance.
Safety Flags & Warnings
Injection Site Reactions
Facial Flushing
Transient Hyperlipidemia
Active Malignancy Contraindication
Geref Withdrawn 2008
Antibody Formation
Always consult a licensed physician. Research purposes only.
€8.6 / mg
